Zambon Biotech has entered into an exclusive deal with Amneal Pharmaceuticals for rights to seek approval and commercialize the oral treatment IPX203 for Parkinson’s disease in the European Union, U.K., and Switzerland. IPX203 is an experimental extended-release formulation of carbidopa and levodopa, designed to ease…

Xadago (safinamide) — approved as an add-on therapy to ease “off periods” that can accompany levodopa — may also help with urinary symptoms in people with Parkinson’s disease, a small study reports. These early findings support previous studies showing that Xadago may be addressing Parkinson’s non-motor symptoms. Larger studies are needed…

Patients in Canada with diagnosed Parkinson’s disease can now receive Onstryv (safinamide) to help manage their symptoms and their “off” episodes. This follows the approval of Onstryv by Health Canada in January 2019 as an add-on treatment to improve motor function in Parkinson’s patients who experience…

Onstryv (safinamide) has been approved for the treatment of Parkinson’s disease in Canada, where roughly 100,000 individuals live with the disorder. The announcement was made by Quebec-based Valeo Pharma and Italian pharmaceutical conglomerate Zambon, the commercialization partner of Newron Pharmaceuticals, a biopharmaceutical company focused on the development…

Xadago (safinamide) has been approved in Australia as an add-on therapy to a treatment regimen that includes levodopa for adults with idiopathic (no genetic or other known cause) Parkinson’s disease. This decision by the Therapeutic Goods Administration of the Australian Government Department of Health adds Australia to the list of…

Italian pharmaceutical conglomerate Zambon has partnered with Montreal-based Valeo Pharma to bring Xadago (safinamide) to Canada, where 100,000 patients living with Parkinson’s disease (PD) will now have access to this recently approved drug. Xadago was developed by Italy’s Newron Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA)…

Italy-based biopharma Newron Pharmaceuticals S.p.A. and its partner, international pharmaceutical company Zambon S.p.A., both dedicated to finding treatments for diseases of the central nervous system (CNS), recently announced their acknowledgement and support of World Parkinson’s Disease Awareness Day, which was on April 11. Additionally, both companies emphasized their commitment to…

Zambon S.p.A. and partner Newron Pharmaceuticals S.p.A. have announced the expansion of its European market by launching Xadago (safinamide) to treat mid- to late-stage Parkinson’s disease (PD) in Italy. The drug is already available in Switzerland, Germany, and Spain. Xadago is an add-on therapy to a stable dose…

Italian pharmaceutical company Zambon S.p.A. and Newron Pharmaceuticals S.p.A. have announced plans to launch Xadago, a drug therapy for mid- to late-stage Parkinson’s disease, in Germany. The release of the treatment is the result of a partnership between the two companies, and Germany will become the first country to commercialize the drug. “The launch of…